Edesa Biotech
EDSA
17 hedge funds and large institutions have $645K invested in Edesa Biotech in 2024 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.
43% more capital invested
Capital invested by funds: $451K → $645K (+$194K)
1.28% more ownership
Funds ownership: 3.4% → 4.68% (+1.3%)
0% more funds holding
Funds holding: 17 → 17 (0)
0% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CM
CM Management
Gulf Breeze,
Florida
|
+$125K |
| 2 |
CIBC World Market
Toronto,
Ontario, Canada
|
+$48K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$17.1K |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.66K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$80 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$589 |
| 2 |
Wells Fargo
San Francisco,
California
|
-$71 |
EDSA Hedge Fund Activity: Q2 2024 in Review
17 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Edesa Biotech (EDSA) for Q2 2024, worth a combined $645K — up 43% from $451K a quarter earlier.
Fund positioning in EDSA was balanced in Q2 2024: 2 funds opened new positions, 2 closed out, 3 added to existing stakes and 0 trimmed.
The largest buyer was CM Management, adding an estimated $125K. The largest seller was Fidelity Investments, exiting entirely with an estimated $589 sold.
- 17 institutional investors held Edesa Biotech (EDSA) as of Q2 2024, unchanged from Q1 2024.
- Funds reported $645K of Edesa Biotech stock for Q2 2024, up 43% quarter-over-quarter.
- 2 funds opened new Edesa Biotech positions in Q2 2024 and 2 closed out, a net change of 0 holders.
- The largest Edesa Biotech buyer in Q2 2024 was CM Management, an estimated $125K added.
- The largest Edesa Biotech seller in Q2 2024 was Fidelity Investments, an estimated $589 sold.
Based on aggregated 13F filings for Q2 2024.